Zeneca Inc., a wholly-owned subsidiary of the UK-based Zeneca Group PLC (NYSE: ZEN), filed suit against Eli Lilly & Co. (NYSE: LLY) in U.S. District Court for the Southern District of New York to stop Lilly's promotion of EVISTA(R) (raloxifene HCl). The suit seeks to, among other things, force Eli Lilly to cease its campaign aimed at misleading physicians and patients that EVISTA has been proven to reduce the incidence of breast cancer. In fact, EVISTA has been approved solely for the prevention of osteoporosis and, according to the FDA, "the effectiveness of raloxifene in reducing the risk of breast cancer has not been established." According to Zeneca, NOLVADEX is the only drug that has been proven effective for the reduction of the incidence of breast cancer in high risk women.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat